RYMTI 50 MG / 1 ML — DIN 02530295
ETANERCEPT : 50 MG / 1 ML · LUPIN PHARMA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is RYMTI?
RYMTI 50 MG / 1 ML contains ETANERCEPT : 50 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02530295, held by LUPIN PHARMA CANADA LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 05-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RYMTI used for?
RYMTI (etanercept) is indicated for: treatment of moderately to severely active rheumatoid arthritis (RA) in adults; reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years; reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA); reducing signs and symptoms of active ankylosing spondylitis (AS); treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy; and treatment of pediatric patients ages 4 to 17 years with chronic severe PsO who are candidates for systemic therapy or phototherapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Etanercept cost around the world?
Etanercept is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 4 | 177 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 3 | 16 | NOK███.██ |
| Luxembourg | reimbursement | 15 | 15 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 13 | CZK███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Italy | ex-factory (classe H) | 12 | 12 | EUR███.██ |
| Hungary | producer price (ex-factory) | 11 | 11 | HUF███.██ |
| Iceland | max wholesale | 3 | 11 | ISK███.██ |
| Slovakia | categorised final price | 11 | 11 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 10 | 10 | EUR███.██ |
| Saudi Arabia | public | 5 | 10 | SAR███.██ |
| United Arab Emirates | public | 4 | 9 | AED███.██ |
| Bahrain | retail (max) | 3 | 9 | BHD███.██ |
| Romania | max producer price | 5 | 8 | RON███.██ |
| South Africa | single exit price | 5 | 7 | ZAR███.██ |
331 pack listings across 108 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Etanercept pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Etanercept in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Etanercept, across 10 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 3 | 3 | ERELZI | Sourceable in Canada |
| LUPIN PHARMA CANADA LIMITED | 3 | 2 | RYMTI | Sourceable in Canada |
| SAMSUNG BIOEPIS CO., LTD | 2 | 2 | BRENZYS | Sourceable in Canada |
| IMMUNEX CORPORATION | 2 | 1 | ENBREL | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG / 1 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | RYMTI single-use prefilled syringes are available in 25 mg (0.5 mL of a 50 mg/mL solution of etanercept) and 50 mg (1.0 mL of a 50 mg/mL solution of etanercept) dosage strengths. RYMTI single-use prefilled autoinjectors are available in a 50 mg (1.0 mL of a 50 mg/mL solution of etanercept) dosage strength. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Etanercept |
|---|---|
| ATC code | L04AB01 |
| AHFS class | 90:24.16.92 |
| Biosimilar biologic | Yes |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02530295 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2530295 |
| Brand name | RYMTI |
| Generic / active ingredient | ETANERCEPT : 50 MG / 1 ML |
| Market authorization holder | LUPIN PHARMA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L04AB01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AB |
| Current status | MARKETED |
| Status date | 05-Apr-2024 |
| Original market date | 2024-04-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRENZYS | 50 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | 02455323 |
| BRENZYS | 50 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | 02455331 |
| ENBREL | 50 MG | SOLUTION | IMMUNEX CORPORATION | MARKETED | 02274728 |
| ERELZI | 25 MG / 0.5 ML | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02462877 |
| ERELZI | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02462850 |
| ERELZI | 50 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02462869 |
| RYMTI | 50 MG / 1 ML | SOLUTION | LUPIN PHARMA CANADA LIMITED | MARKETED | 02530309 |
| ENBREL | 1 ML | LIQUID ; POWDER FOR SOLUTION ; KIT | IMMUNEX CORPORATION | CANCELLED POST MARKET | 02242903 |
| RYMTI | 25 MG / 0.5 ML | SOLUTION | LUPIN PHARMA CANADA LIMITED | APPROVED | 02530287 |
2 · Same class — other molecules in ATC L04AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Adalimumab | ABRILADA · AMGEVITA · HADLIMA · HADLIMA PUSHTOUCH · +6 more | 41 | 34 | Yes |
| Etanercept | BRENZYS · ENBREL · ERELZI · RYMTI | 10 | 8 | Yes |
| Infliximab | AVSOLA · IXIFI · OMVYENCE · REMDANTRY · +4 more | 9 | 6 | Yes |
| Golimumab | LIVMOTY · SIMPONI · SIMPONI I.V. | 9 | 5 | Yes |
| Certolizumab Pegol | CIMZIA | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is RYMTI called?
The same molecule, Etanercept, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Enbrel | Latin | Australia, Bahrain, Czechia, Iceland, Norway |
| Erelzi | Latin | Australia, Bahrain, Czechia, Iceland, Norway, Saudi Arabia |
| Nepexto | Latin | Australia, Bahrain, Czechia, Saudi Arabia |
| Brenzys | Latin | Australia, Saudi Arabia |
| Benepali | Latin | Czechia, Iceland, Norway |
| ENBREL PRO PEDIATRICK� POU�IT� | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.